Zydus US036
Welcome,         Profile    Billing    Logout  
 0 Trials 
9 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Valence, Brittany
EPICS-III, NCT05133336 / 2022-001634-10: Saroglitazar Magnesium for Treatment of Primary Biliary Cholangitis

Completed
2/3
196
US, RoW
Saroglitazar Magnesium 1 mg, Saroglitazar Magnesium 2 mg, Placebo
Zydus Therapeutics Inc., Zydus Therapeutics Inc.
Primary Biliary Cholangitis
04/25
05/25
NCT04809376: Treatment Effects of Subcutaneous Injections of Pentosan Polysulfate Sodium vs Placebo in Participants With Knee OA Pain

Active, not recruiting
2/3
602
US, RoW
Pentosan Polysulfate Sodium twice weekly, PPS twice weekly, Placebo (Sodium Chloride Injection, 0.9%), Placebo, Pentosan Polysulfate Sodium Fixed Dose, Fixed Dose, Pentosan Polysulfate Sodium once weekly, PPS once weekly
Paradigm Biopharmaceuticals USA (INC)
Osteoarthritis, Knee
10/24
01/25
EIP21-NFD-504, NCT05869669: RewinD-LB - Clinical Study of Neflamapimod in Patients with Dementia with Lewy Bodies

Active, not recruiting
2
159
Europe, US
Neflamapimod, VX-745, Placebo
EIP Pharma Inc, National Institute on Aging (NIA), Worldwide Clinical Trials, CervoMed, Inc
Dementia with Lewy Bodies
10/24
06/25
NCT05832151: A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adults With Diabetic Gastroparesis

Recruiting
2
360
US
CIN-102 Dose 15mg or 10mg, Placebo
CinDome Pharma, Inc.
Diabetic Gastroparesis
09/25
09/25
EvolvE, NCT05774184 / 2022-001786-12: A Study of CDX-0159 in Patients With Eosinophilic Esophagitis

Active, not recruiting
2
86
Europe, Canada, US, RoW
barzolvolimab, Matching Placebo
Celldex Therapeutics, Celldex Therapeutics, Inc.
Eosinophilic Esophagitis
06/25
12/25
NCT06163404: Open-Label Study to Evaluate the Safety and Effectiveness of the Spirair Implant

Active, not recruiting
N/A
102
US
Implantation of Spirair Nasal Device using the Spirair delivery system., SeptAlign
Spirair, Inc
Nasal Septal Deviation, Nasal Airway Obstruction
09/25
05/27
NA-PAS, NCT04836546: Eversense® Non-adjunctive Use Post Approval Study

Recruiting
N/A
925
US
Blood glucose meter, Eversense CGM System
Senseonics, Inc.
Diabetes
03/26
03/26
Fields, Alyce
EPICS-III, NCT05133336 / 2022-001634-10: Saroglitazar Magnesium for Treatment of Primary Biliary Cholangitis

Completed
2/3
196
US, RoW
Saroglitazar Magnesium 1 mg, Saroglitazar Magnesium 2 mg, Placebo
Zydus Therapeutics Inc., Zydus Therapeutics Inc.
Primary Biliary Cholangitis
04/25
05/25
VENTURE, NCT06068946: VK2735 for Weight Management Phase 2

Completed
2
176
US
VK2735, Placebo
Viking Therapeutics, Inc.
Weight Loss
02/24
04/24
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Valence, Brittany
EPICS-III, NCT05133336 / 2022-001634-10: Saroglitazar Magnesium for Treatment of Primary Biliary Cholangitis

Completed
2/3
196
US, RoW
Saroglitazar Magnesium 1 mg, Saroglitazar Magnesium 2 mg, Placebo
Zydus Therapeutics Inc., Zydus Therapeutics Inc.
Primary Biliary Cholangitis
04/25
05/25
NCT04809376: Treatment Effects of Subcutaneous Injections of Pentosan Polysulfate Sodium vs Placebo in Participants With Knee OA Pain

Active, not recruiting
2/3
602
US, RoW
Pentosan Polysulfate Sodium twice weekly, PPS twice weekly, Placebo (Sodium Chloride Injection, 0.9%), Placebo, Pentosan Polysulfate Sodium Fixed Dose, Fixed Dose, Pentosan Polysulfate Sodium once weekly, PPS once weekly
Paradigm Biopharmaceuticals USA (INC)
Osteoarthritis, Knee
10/24
01/25
EIP21-NFD-504, NCT05869669: RewinD-LB - Clinical Study of Neflamapimod in Patients with Dementia with Lewy Bodies

Active, not recruiting
2
159
Europe, US
Neflamapimod, VX-745, Placebo
EIP Pharma Inc, National Institute on Aging (NIA), Worldwide Clinical Trials, CervoMed, Inc
Dementia with Lewy Bodies
10/24
06/25
NCT05832151: A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adults With Diabetic Gastroparesis

Recruiting
2
360
US
CIN-102 Dose 15mg or 10mg, Placebo
CinDome Pharma, Inc.
Diabetic Gastroparesis
09/25
09/25
EvolvE, NCT05774184 / 2022-001786-12: A Study of CDX-0159 in Patients With Eosinophilic Esophagitis

Active, not recruiting
2
86
Europe, Canada, US, RoW
barzolvolimab, Matching Placebo
Celldex Therapeutics, Celldex Therapeutics, Inc.
Eosinophilic Esophagitis
06/25
12/25
NCT06163404: Open-Label Study to Evaluate the Safety and Effectiveness of the Spirair Implant

Active, not recruiting
N/A
102
US
Implantation of Spirair Nasal Device using the Spirair delivery system., SeptAlign
Spirair, Inc
Nasal Septal Deviation, Nasal Airway Obstruction
09/25
05/27
NA-PAS, NCT04836546: Eversense® Non-adjunctive Use Post Approval Study

Recruiting
N/A
925
US
Blood glucose meter, Eversense CGM System
Senseonics, Inc.
Diabetes
03/26
03/26
Fields, Alyce
EPICS-III, NCT05133336 / 2022-001634-10: Saroglitazar Magnesium for Treatment of Primary Biliary Cholangitis

Completed
2/3
196
US, RoW
Saroglitazar Magnesium 1 mg, Saroglitazar Magnesium 2 mg, Placebo
Zydus Therapeutics Inc., Zydus Therapeutics Inc.
Primary Biliary Cholangitis
04/25
05/25
VENTURE, NCT06068946: VK2735 for Weight Management Phase 2

Completed
2
176
US
VK2735, Placebo
Viking Therapeutics, Inc.
Weight Loss
02/24
04/24

Download Options